What is CJC-1295?
CJC-1295 is a GHRH analogue studied in growth hormone release models, with DAC and non-DAC forms discussed separately in research.
CJC-1295 dosage snapshot
- Route
- subQ
- Dose range
- 1-2 mg
- Frequency
- 1-2x weekly
- Duration
- 8-12 weeks
Based on reported research sources; not a dosing instruction.
Potential benefits
- Recovery support
- Tissue repair
- Mobility
- Body composition
- Training adaptation
Safety profile
Unknown risk- Common: Route-specific irritation or tolerability issues may be reported depending on the compound.
- Less common: Headache, fatigue, appetite changes, or GI discomfort can appear in community or study contexts.
- Caution: Risk depends on dose, route, study model, duration, compound quality, and whether human data exists.
Storage and handling
Store according to product-label instructions and batch handling notes. Lyophilized research peptides are commonly kept dry, protected from light, and handled with clean laboratory technique.